London
· Delayed Price · Currency is GBP · Price in USD bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of GBP 60.62 million. The enterprise value is 305.55 million.
| Market Cap | 60.62M |
| Enterprise Value | 305.55M |
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +72.23% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 9.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.40 |
| EV / Sales | 7.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.53 |
Financial Position
The company has a current ratio of 0.51
| Current Ratio | 0.51 |
| Quick Ratio | 0.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.40 |
| Interest Coverage | -15.24 |
Financial Efficiency
Return on equity (ROE) is -270.20% and return on invested capital (ROIC) is -44.45%.
| Return on Equity (ROE) | -270.20% |
| Return on Assets (ROA) | -36.91% |
| Return on Invested Capital (ROIC) | -44.45% |
| Return on Capital Employed (ROCE) | -188.42% |
| Revenue Per Employee | 140,542 |
| Profits Per Employee | -774,740 |
| Employee Count | 375 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -62.52% |
| 50-Day Moving Average | 8.03 |
| 200-Day Moving Average | 14.09 |
| Relative Strength Index (RSI) | 48.70 |
| Average Volume (20 Days) | 1,152 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.85 |
Income Statement
In the last 12 months, bluebird bio had revenue of GBP 39.63 million and -218.48 million in losses. Loss per share was -25.04.
| Revenue | 39.63M |
| Gross Profit | -19.15M |
| Operating Income | -237.61M |
| Pretax Income | -218.54M |
| Net Income | -218.48M |
| EBITDA | -195.68M |
| EBIT | -237.61M |
| Loss Per Share | -25.04 |
Balance Sheet
The company has 52.71 million in cash and 279.86 million in debt, giving a net cash position of -227.15 million.
| Cash & Cash Equivalents | 52.71M |
| Total Debt | 279.86M |
| Net Cash | -227.15M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -4.32M |
| Book Value Per Share | -0.45 |
| Working Capital | -108.35M |
Cash Flow
In the last 12 months, operating cash flow was -196.96 million and capital expenditures -2.48 million, giving a free cash flow of -199.45 million.
| Operating Cash Flow | -196.96M |
| Capital Expenditures | -2.48M |
| Free Cash Flow | -199.45M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -48.31% |
| Operating Margin | -599.54% |
| Pretax Margin | -551.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -72.23% |
| Shareholder Yield | -72.23% |
| Earnings Yield | -360.42% |
| FCF Yield | -329.03% |
Stock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
bluebird bio has an Altman Z-Score of -15.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.68 |
| Piotroski F-Score | n/a |